Overall response rate of 70.1% and complete response rate of 33.3% in heavily pretreated patients; median duration of response of 13.7 months
Safety profile substantially consistent with prior findings
Preparing for potential submission of a Biologics License Application to the FDA
Cami data and diffuse large B-cell lymphoma posters to be presented today at the European Hematology Association 2022 Hybrid Congress
https://finance.yahoo.com/news/adc-therapeutics-announces-results-pivotal-070000963.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.